Clinical Trials Using Anti-GD2 Monoclonal Antibody hu14.18K322A

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-GD2 Monoclonal Antibody hu14.18K322A. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Anti-GD2 Monoclonal Antibody Hu14.18K322A and Combination Chemotherapy before Autologous Stem Cell Transplant and Radiation Therapy in Treating Younger Patients with Previously Untreated High-Risk Neuroblastoma

    This phase II trial studies how well anti-GD2 monoclonal antibody hu14.18K322A and combination chemotherapy before autologous stem cell transplant and radiation therapy works in treating younger patients with previously untreated high-risk neuroblastoma. Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as anti-GD2 monoclonal antibody hu14.18K322A, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee